GlassScriptPhysician profile
Ian Michael Wall
NPI 1528170792
$7,982.75
in general payments reported to CMS, 2019-2025
35 companies · $2,438 in 2025
The $2,438 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $429 · 2021: $930 · 2022: $734 · 2023: $1,164 · 2024: $1,521 · 2025: $2,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,119 · Consulting Fee: $950 · Education: $54.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,119.24 |
| Consulting Fee | $950.00 |
| Education | $54.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,722.20 | 2019-2025 | Mavyret, Viberzi, Linzess |
| E.R. Squibb & Sons, L.L.C. | $667.15 | 2021-2024 | Zeposia |
| Celgene Corporation | $567.31 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $520.85 | 2019-2025 | |
| Pfizer INC. | $452.14 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.78 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $363.21 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $313.28 | 2020-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $312.44 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $227.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Romark Laboratories, Lc | $218.84 | 2019-2020 | |
| Vivus LLC | $150.66 | 2021-2025 | Pancreaze |
| Redhill Biopharma INC. | $120.83 | 2020-2024 | Talicia |
| Ardelyx, INC. | $120.05 | 2022-2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $95.40 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $92.96 | 2021-2023 | |
| Lilly USA, LLC | $61.17 | 2024 | Zepbound, Omvoh |
| Celltrion USA INC. | $59.52 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $59.44 | 2021 | |
| Allergan, INC. | $58.23 | 2019-2020 | |
| Braintree Laboratories, INC. | $51.66 | 2019-2021 | |
| Novo Nordisk INC | $45.34 | 2025 | Wegovy |
| Qol Medical, LLC | $37.63 | 2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $32.83 | 2019-2020 | |
| Genzyme Corporation | $30.37 | 2024 | |
| W. L. Gore & Associates, INC. | $29.00 | 2022 | |
| Intra-Sana Laboratories | $28.62 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Intercept Pharmaceuticals, INC. | $24.18 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Exact Sciences Corporation | $20.76 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $18.15 | 2019 | |
| Ucb, INC. | $17.61 | 2019 | |
| Currax Pharmaceuticals LLC | $16.67 | 2022 | |
| Alfasigma USA, INC. | $15.26 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $12.92 | 2024 | Sureclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Michael Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.